A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers
- Conditions
- Advanced Malignant Solid Tumors
- Interventions
- Drug: CM082 with fed or fasting
- Registration Number
- NCT04126668
- Lead Sponsor
- AnewPharma
- Brief Summary
The main objective of this study is to evaluate the Effect of Food on the Pharmacokinetics of CM082 tablet.
- Detailed Description
The main objective of this study is to evaluate the Effect of Food on the Pharmacokinetics of CM082 tablet in Chinese Healthy Volunteers. In addition, the safety of CM082 tablet in Chinese Healthy Volunteers who with High-fat meal or fasting state will also be evaluated.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
- age: 18 - 45 years;
- sex: male and female;
- body weight: Male ≥ 50 kg,female ≥ 45 kg, body mass index BMI (weight (kg)/height 2 (m2)) between 19-26 kg/m2 (including border);
- Healthy as judged by the investigator/subinvestigator based on the results of physical examinations and all lab tests;
- Abstinence or physical contraception approved by researchers must be approved during and within three months after the trial is completed; and no sperm and egg donation plan is available；
- Written informed consent;
- Received any investigational drugs within 14 days before the screening test;
- Donated 200 mL of whole blood within 30 days before the screening test,or donated 200 mL of whole blood during the study or within 30 days after completion of the study;
- Females who are lactating, pregnant, potentially child-bearing, or willing to get pregnant during the study period;
- History of drug or food allergies;
- Abnormal blood pressure or pulse，Abnormal laboratory tests;
- Participated in other clinical trials within 3 months before screening;
- Smoking and drinking within 3 months before screening or test results of smoke, alcohol, and drug abuse are positive;
- Positive for HBsAg, Hepatitis C virus (HCV) antibody, HIV antibody or syphilis antibody;
- Clinically apparent disease/infection within 1 month before screening;
- The researchers determined that there were other conditions that were not suitable for the trial;
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Period 1: fasted control → Period 2: fed control CM082 with fed or fasting Period 1: administration of CM082 200 mg at 7:30am, without the breakfast；Period 2: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast Period 1: fed control → Period 2: fasted control CM082 with fed or fasting Period 1: administration of CM082 200 mg at 7:30am, 30 minutes after the breakfast；Period 2: administration of CM082 200 mg at 7:30am, without the breakfast
- Primary Outcome Measures
Name Time Method Peak plasma concentration (Cmax) of CM082 pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration) The effect of food on Cmax after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions
Area under the plasma concentration versus time curve (AUC) of CM082 pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration) The effect of food on AUC after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions
Time of maximum concentration（Tmax）of CM082 pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration) The effect of food on Tmax after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions
Half life（T1/2）of CM082 pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration) The effect of food on T1/2 after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions
- Secondary Outcome Measures
Name Time Method Percentage of adverse events From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 months Percentage of adverse events as assessed by CTCAE v4.03
Trial Locations
- Locations (1)
The 1st Phase Clinical Research Center of the Second Affiliated Hospital of Zhejiang University Medical College
🇨🇳Hangzhou, Zhejiang, China